NEW YORK – Dermatologic diagnostics company Castle Biosciences said on Tuesday that it has been awarded a five-year US Federal Supply Schedule contract by the Veterans Health Administration for its DecisionDx-Melanoma gene expression profile test.
Financial terms of the contract were not disclosed.
The VHA is a component of and implements the healthcare program for US veterans through the US Department of Veterans Affairs. The contract, which became effective on Aug. 15, provides greater access to DecisionDx-Melanoma for veterans being treated through the VHA, as well as active duty service members and their families seeking medical treatment through the military's health system, Friendswood, Texas-based Castle Bio said.
"We believe that adding the personalized genomic information provided by our DecisionDx-Melanoma test to traditional clinical and pathology factors can help clinicians make improved treatment decisions for their [skin cancer] patients," Castle Bio CEO Derek Maetzold said in a statement. "This contract provides veterans and active-duty service members treated in VA and [military health system] medical centers greater access to our test, allowing them to incorporate DecisionDx-Melanoma into their management plans."